OKYO Pharma (OKYO) announced the appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer. Dr. Mantelli led the clinical development, regulatory approval, and global medical strategy of Oxervate at Dompe farmaceutici S.p.A.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKYO:
- OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial
- OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting
- OKYO Pharma Wins FDA Backing on Phase 2b/3 Design for Urcosimod in Neuropathic Corneal Pain
- Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod
- OKYO Pharma Wins FDA Compassionate-Use Clearance for Urcosimod in Severe Neuropathic Corneal Pain